HealthDecember 19, 2023

Implementing preauthorization and prospective feedback in your antimicrobial stewardship program

Preauthorization and prospective audit and feedback have long been recommended as evidence-based interventions to improve antimicrobial use. 

The Infectious Diseases Society of America strongly recommends their adoption in their 2016 Guidelines on Implementing an Antibiotic Stewardship Program. In the 2023 update to the Joint Commission Medication Management standards MM.09.01.01, element of performance 17 requires ASP to implement one or both of the following:

  • Preauthorization for specific antibiotics that includes an internal review and approval process prior to use
  • Prospective review and feedback regarding antibiotic prescribing practices, including the treatment of positive blood cultures, by a member of the antibiotic stewardship program

Preauthorization requires the clinician to obtain approval from antimicrobial stewards before prescribing selected antimicrobials. Typically, these selected antimicrobials may include: 

  • Broad-spectrum agents
  • Drugs subject to misuse
  • Antibiotics with a high incidence of adverse reactions and/or severe adverse reactions regardless of incidence
  • High-cost agents

Prospective audit and feedback refer to reviewing and discussing a patient’s antimicrobial therapy with the ordering clinician after the antimicrobial was prescribed. The audit and feedback may or may not result in a change in therapy. Based on the Joint Commission requirements mentioned above, AMS leaders should also review the treatment of positive blood cultures.

For hospitals that have not implemented either of these interventions, we will discuss the recommended steps to launch these interventions.

Considerations in implementing preauthorization 

Engage with key stakeholders

 Preauthorizations are often associated with the administrative burdens imposed on outpatient prescriptions by insurance companies. Therefore, the word preauthorization can be emotionally charged with prescribing clinicians. Antimicrobial stewards should craft their message to distinguish the purpose of this intervention from the cost-saving aim imposed by insurance payers. The goal is to improve the use of antimicrobials and reduce the pace of resistance development to broad-spectrum and/or newly approved antimicrobials. We encourage stewards to take the time to listen to the prescriber and incorporate their concerns into designing processes to ensure that therapies are not delayed if prescribed appropriately.

Secure resources from leadership

Implementation of preauthorization requires significant financial, human, and technological resources. Leadership must commit to providing the resources to support a preauthorization program. Stewards must determine who and how antimicrobials will be approved 24/7. Hospitals with infectious diseases physicians on staff will typically rely on their expertise and on-call coverage to provide this service. The hospitals will need to establish reimbursement for the provision of this service. This may be in the form of a flat fee or a per-call fee. Pharmacists unfamiliar with physician reimbursement may wish to discuss the process with their medical staff office to determine how to provide this reimbursement to their physicians.

In hospitals without access to infectious diseases physicians, the approver may be an infectious diseases-trained pharmacist or a clinical pharmacy manager. Depending on the volume of authorization requests, pharmacy leadership should ensure adequate coverage and plan to offset any tasks required of the approving pharmacists.

Select antimicrobials requiring preauthorization

As discussed earlier, AMS leaders may often select drugs that are broad-spectrum, likely to be misused, or with severe and/or high incidence of adverse reactions to include in the program. You may also wish to review your past antibiograms to determine if there are any potential resistance trends or leverage benchmarks such as Standardized Antimicrobial Administration Ratios (SAAR) to identify drugs for inclusion in this program.

Design the preauthorization program

Even though it appears obvious to many, AMS leaders may wish to diagram the medication use process and determine how to implement the preauthorization process best. Some items to consider include:

  • How do you indicate restricted antimicrobials in CPOE so prescribers will know they require preauthorization?
  • How does a prescriber request authorization?
  • Who would approve or deny the request?
  • What criteria are used to assess the appropriateness of each antimicrobial? In programs where pharmacists review the requests, we recommend that AMS leaders work with medical staff to establish such criteria using as much objective clinical data as possible.
  • How would the approval and denial be communicated to the prescriber and pharmacy?
  • What alternative treatment would you recommend to the prescriber if the requested antimicrobial is not approved?

Communicate the process with medical staff, nurses, and pharmacists

As you diagram the medication use process, the AMS leader should share the logistics with relevant stakeholders before the program's rollout. The stakeholders have different interests, and their concerns must be addressed to ensure a successful rollout. For instance, prescribers may view this program as infringing on their autonomy. In contrast, nurses may be under pressure from their managers and quality departments to administer antibiotics as soon as possible due to regulatory pressure from the SEP-1 bundle.

Adjudication/appeal process

In conjunction with the medical staff and compliance with applicable policies and by-laws, the AMS leaders should spell out the process to appeal a decision. During the appeal process, it would help to consider how to provide a suitable antimicrobial, including the requested drug. Many hospitals will have the ultimate appeal decision rest with the chair of the medical staff. In addition, AMS leaders should spell out the service-level expectations for the authorizations. For example, a call back within 30 minutes, or the pharmacy may dispense a dose to minimize any delay that could jeopardize the patient’s outcome as the request works through the process.

Metric collection

As with any performance improvement process, AMS leaders shall collect information such as the number of requisitions, % approvals, reasons for denials, turnaround times, and antimicrobial utilization such as Days of Therapy to measure program performance.

Considerations for implementing prospective feedback 

Engage with key stakeholders

Prospective feedback is often provided by the AMS team or a pharmacist to the prescriber. Before the program's rollout, AMS leaders should communicate the program's intent and address any concerns.

Secure resources from leadership

Implementation of prospective feedback requires dedicated time by the feedback providers to review antimicrobial orders. The reviewer should not be tasked with other activities, such as order verifications or dispensing medications. Pharmacy leadership should also provide coverage for weekends and vacations to ensure the continuity of the program. Technology resources may also be needed to generate a list of patients due for review and provide a workflow to document reviews and pharmacist intervention. While some electronic health records can generate a list of patients with antimicrobial orders of interest, many programs prefer to keep notes related to these reviews off individual patients’ charts. These reviews are sometimes classified as quality or performance improvement initiatives, and review documentation is not considered part of the individual patient’s medical record. AMS leaders should consider how to keep track of these reviews. Cloud-based clinical surveillance tools, like Sentri7, may help record performance improvement activity documentation.

Select antimicrobials and infections for review

AMS leaders may use methods similar to those listed above in the preauthorization to select drugs for inclusion in this initiative. Based on the prescriptive Joint Commission element of performance, AMS program should include any positive blood cultures for review and provide feedback. Clinical surveillance solutions can help identify patients with positive blood cultures and provide an audit trail to demonstrate to the Joint Commission your performance of these activities.

Communicate process with medical staff

When ready to launch the prospective feedback process, we recommend working with the medical staff leadership to communicate the program's purpose and logistics. While feedback and recommendations provided are non-compulsory, demonstration of support from medical staff leadership will help increase the credibility of the program when the feedback provider contacts the prescribing physician to provide feedback.

Documentation

Since the ultimate responsibility for the patient rests with the prescribing physician, prospective feedback and treatment recommendations may not always be accepted. AMS leaders should document the acceptance and rejection of each discussion. If rejection trends are observed with a particular clinician or a particular type of recommendation, a more comprehensive panel of physicians and pharmacists may be convened to perform case reviews. Once again, many jurisdictions do not consider documentation of these activities as part of an individual patient’s electronic health record; AMS leaders should consider documenting their activities without leaving a formal note on the patient’s chart.

Metric collection

AMS leaders should record the volume of reviews, the % of reviews performed on included drugs/infections, outcomes of interventions, and antimicrobial utilization to measure program performance and identify opportunities for future improvement.

Learn About Sentri7 Pharmacy
Steve-Mok
Manager of Pharmacy Services and Fellowship Director
Dr. Steve Mok has over a decade of experience in the areas of antimicrobial stewardship, infectious diseases and clinical pharmacy management. He has practiced in a variety of settings.
Solutions
Sentri7® Pharmacy
Sentri7 Pharmacy identifies patients early and accurately to improve patient care, safety, and drive pharmacy cost savings by optimizing medication therapies.
Empower your pharmacy team to impact patient care through evidence-based recommendations, standardizing practices via pharmacy-specific workflows, and using robust analytics to drive improvements in medication therapy, Opioid Stewardship, and Antimicrobial Stewardship.
Back To Top